2025 · Poster Presentation · Genentech · Hepatology
Director of Clinical Epidemiology and Scientific Publications
Heather L. Morris
Dr. Heather Morris is currently serving as the Director for Clinical Epidemiology and Scientific Publications for Target RWE Health Evidence Solutions. In her role at Target RWE, Dr. Morris contributes to the design of research in the HCC, NASH, and COVID-19 communities. Prior to joining Target RWE, Heather was the Associate Director for Population Health for the OneFlorida Clinical Research Consortium at the University of Florida. In this role, she was an active member on the Diabetes and Obesity Collaborative working group through the Patient-Centered Outcomes Research Institute and was a site PI for a number of multi-site PCORI Rapid Cycle Research projects.
For six years, Dr. Morris was the faculty lead for the external quality review of Florida Children’s Medical Services Managed Care Plan in the Department of Health Outcomes and Biomedical Informatics. While overseeing contract work, Dr. Morris also collaborated with investigators primarily in endocrinology with projects focused on promoting health equity for patients with Type 1 Diabetes, developing a computable phenotype to accurately identify pediatric patients with Type 1 Diabetes, assessing prevalence and incidence of Type 2 Diabetes at PCORI sites, and a project using machine learning to develop a computable phenotype to identify patients with non-alcoholic fatty liver disease. Dr. Morris received her PhD from Virginia Commonwealth University in 2014.

Publications
37
Total Publications
2025 · Abstract/Manuscript · UNC
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH
Read more →2025 · Abstract/Manuscript · Kings College of London
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease
Read more →2025 · Abstract/Manuscript
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy
Read more →2025 · Poster Presentation · Saint Louis University · Hepatology
Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort
Read more →2025 · Poster Presentation · Madrigal · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions
Read more →2025 · Poster Presentation · German Diabetes Center (DDZ) / Heinrich Heine University Düsseldorf · Hepatology
Type 2 Diabetes and Obesity are The Main Metabolic Risk Factors for The Development of Cirrhosis in People with Metabolic Dysfunction Associated Steatohepatitis
Read more →2024 · Poster Presentation · German Diabetes Center (DDZ) / Heinrich Heine University Düsseldorf · Hepatology
Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status
Read more →2024 · Poster Presentation · Merck · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort
Read more →2024 · Poster Presentation · Merck · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort
Read more →2024 · Poster Presentation · Novo Nordisk · Hepatology
Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH
Read more →2024 · Poster Presentation · Saint Louis University · Hepatology
A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Read more →2024 · Poster Presentation · Madrigal · Hepatology
Non-invasive tests as a prediction tool to assess MASH resolution score
Read more →2024 · Poster Presentation · Madrigal · Hepatology
A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH
Read more →2024 · Abstract/Manuscript · Duke
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort
Read more →2024 · Abstract/Manuscript · Heinrich Heine University Dusseldorf/German Diabetes Center
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort
Read more →2024 · Poster Presentation · Heinrich Heine University Düsseldorf · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH
Read more →2024 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Factors Predicting Loss of Remission in Crohn's Disease Patients in Endoscopic Remission in the Real World Results From TARGET-IBD
Read more →2023 · Poster Presentation · University of Birmingham / NIHR Birmingham BRC · Hepatology
NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US
Read more →2023 · Poster Presentation · Cleveland Clinic · Hepatology
A Prospective, Pragmatic Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients after Direct-Acting Antiviral (DAA) Therapy: DAA-PASS
Read more →2023 · Poster Presentation · University of Chicago · Gastroenterology
Outcomes of early vs. delayed advanced therapy among patients with moderate ulcerative colitis in the United States: TARGET-IBD
Read more →2023 · Poster Presentation · University of North Carolina at Chapel Hill · Gastroenterology
Treatment Journey among patients with moderate ulcerative colitis in the United States: TARGET-IBD
Read more →2023 · Poster Presentation · University of Birmingham (UK) · Methods/Pharmacoepi
Analysis of discrimination and calibration of two cardiovascular risk scores in patients with non-alcoholic steatohepatitis shows a need for improved accuracy of these models
Read more →2023 · Abstract/Manuscript · Mayo Clinic
Impact of itch on quality of life in people with primary biliary cholangitis: a plain language summary
Read more →2023 · Oral Presentation · Hepatology
Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study
Read more →2022 · Poster Presentation · Saint Louis University · Hepatology
The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH
Read more →2022 · Poster Presentation · Novartis · Hepatology
Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks
Read more →2022 · Poster Presentation · University of Chicago · Gastroenterology
The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn's Disease in TARGET IBD
Read more →2022 · Poster Presentation · Bristol Myers Squibb · Gastroenterology
Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD
Read more →2022 · Poster Presentation · Methods/Pharmacoepi
Healthcare Utilization and Charges Associated with US Hospitalized Adult Patients with COVID 19
Read more →2022 · Poster Presentation · Methods/Pharmacoepi
Association Between Clinical Outcomes and Patient Characteristics Among Hospitalized Adult Patients with COVID-19
Read more →2022 · Abstract/Manuscript · Emory
Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease
Read more →2022 · Abstract/Manuscript · Mayo Clinic
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
Read more →2021 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Factors Associated with Readmission in the US Following Hospitalization with COVID-19
Read more →2019 · Poster Presentation · University of Pennsylvania · Methods/Pharmacoepi